<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know</h2>
    <div class="badge">2025-09-08T15:27:00+00:00</div>
    <ul>
      <li>Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.</li>
<li>The company expects to advance rezpeg into phase III development in the first half of 2026.</li>
<li>Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm</li>
<li>Image Source: Zacks Investment Research NKTR’s Atopic Dermatitis Data on Rezpeg In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis met</li>
<li>Despite amlitelimab meeting all primary and key secondary endpoints in the COAST 1 study, shares of SNY tanked as the data seemed to fall short of investors&#x27; expectations.</li>
<li>Here’s Why NKTR Was Up This Past Week Nektar’s price rose after French drugmaker Sanofi SNY announced data from the phase III COAST 1 study evaluating its pipeline candidate, amlitelimab, for treating moderate-to-severe</li>
<li>However, rezpeg’s long-term efficacy is yet to be determined.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=NKTR Shares Surge 38.2% in a Week: Here&amp;#x27;s What You Should Know\n• Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.\n• The company expects to advance rezpeg into phase III development in the first half of 2026.\n• Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm\n• Image Source: Zacks Investment Research NKTR’s Atopic Dermatitis Data on Rezpeg In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis met\n• Despite amlitelimab meeting all primary and key secondary endpoints in the COAST 1 study, shares of SNY tanked as the data seemed to fall short of investors&#x27; expectations.\n• Here’s Why NKTR Was Up This Past Week Nektar’s price rose after French drugmaker Sanofi SNY announced data from the phase III COAST 1 study evaluating its pipeline candidate, amlitelimab, for treating moderate-to-severe\n• However, rezpeg’s long-term efficacy is yet to be determined." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/nktr-shares-surge-38-2-152700121.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>